1. Home
  2. CEE vs RCEL Comparison

CEE vs RCEL Comparison

Compare CEE & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CEE

The Central and Eastern Europe Fund Inc. (The)

N/A

Current Price

$18.33

Market Cap

128.1M

Sector

Finance

ML Signal

N/A

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

N/A

Current Price

$4.72

Market Cap

132.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CEE
RCEL
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
226
Industry
Finance Companies
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.1M
132.0M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
CEE
RCEL
Price
$18.33
$4.72
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.88
AVG Volume (30 Days)
19.2K
211.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$21.69
Revenue Next Year
N/A
$49.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.20
$3.22
52 Week High
$19.98
$10.28

Technical Indicators

Market Signals
Indicator
CEE
RCEL
Relative Strength Index (RSI) 39.40 51.25
Support Level $16.95 $4.11
Resistance Level $18.35 $5.89
Average True Range (ATR) 0.60 0.37
MACD -0.17 -0.05
Stochastic Oscillator 27.90 4.62

Price Performance

Historical Comparison
CEE
RCEL

About CEE The Central and Eastern Europe Fund Inc. (The)

CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: